Krystal Biotech, Inc. (NASDAQ:KRYS) Short Interest Down 7.4% in January

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,010,000 shares, a decline of 7.4% from the January 15th total of 3,250,000 shares. Based on an average daily volume of 262,600 shares, the days-to-cover ratio is presently 11.5 days.

Analysts Set New Price Targets

KRYS has been the topic of a number of research analyst reports. Chardan Capital reissued a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Wednesday, December 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $206.67.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in Krystal Biotech by 0.5% in the fourth quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after buying an additional 21,133 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after purchasing an additional 28,707 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Krystal Biotech by 0.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock worth $411,831,000 after purchasing an additional 6,600 shares during the last quarter. State Street Corp raised its stake in shares of Krystal Biotech by 9.0% in the third quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after purchasing an additional 119,936 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after purchasing an additional 11,411 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 1.6 %

NASDAQ:KRYS traded down $2.51 during midday trading on Monday, hitting $153.24. 129,478 shares of the company traded hands, compared to its average volume of 236,087. Krystal Biotech has a 12-month low of $107.50 and a 12-month high of $219.34. The firm’s fifty day moving average is $158.61 and its 200-day moving average is $175.74. The firm has a market capitalization of $4.41 billion, a P/E ratio of 86.58 and a beta of 0.84.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).